Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918548 | 0.87 | KMT2A (0.56) | CASP3ALDH1A1MEN1KMT2ACHRM5 | |
| SCHEMBL23910448 | 0.87 | MEN1 (0.58) | CASP3ALDH1A1MEN1KMT2ALIPG | |
| SCHEMBL1839329 | 0.86 | CASP3 (0.69) | CASP3ALDH1A1MEN1KMT2ATRPC5 | |
| SCHEMBL23918746 | 0.86 | ALDH1A1 (0.55) | CASP3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2351123 | 0.84 | CASP3 (0.57) | CASP3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL23918738 | 0.83 | CASP3 (0.51) | CASP3ALDH1A1MEN1KMT2ALIPG | |
| SCHEMBL9206443 | 0.83 | CASP3 (0.50) | CASP3ALDH1A1MEN1KMT2ALIPG | |
| SCHEMBL27760325 | 0.83 | CASP3 (1.00) | CASP3ALDH1A1MEN1KMT2ATRPC5 | |
| SCHEMBL23918756 | 0.82 | ALDH1A1 (0.51) | CASP3ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL24379688 | 0.82 | ALDH1A1 (0.53) | CASP3ALDH1A1MEN1KMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118649185-B | Pharmaceutical composition for inhibiting enterococcus faecalis and application thereof | 昆明市延安医院(昆明市干部疗养院) | 2025-03-04 | — | — | CN | claimed |
| CN-118649185-A | Pharmaceutical composition for inhibiting enterococcus faecalis and application thereof | 昆明市延安医院(昆明市干部疗养院) | 2024-09-17 | — | — | CN | claimed |
| US-11504406-B2 | Probiotic and probiotic combination for inhibition of vancomycin-resistant enterococci and use thereof | DELTA ELECTRONICS, INC. (TW) | 2022-11-22 | — | — | US | claimed |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4661910-A2 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4662196-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250367131-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | George Mason Research Foundation, Inc. | 2025-12-04 | — | — | US | disclosed |
| US-20250360199-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | US HEALTH (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250352636-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | CureVac SE (DE) | 2025-11-20 | — | — | US | disclosed |
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20060062822-A1 | Medical devices to treat or inhibit restenosis | MEDTRONIC VASCULAR, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-20050004225-A1 | Oxidoreductase inhibitors and methods of screening and using thereof | CITY OF HOPE | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576040-B2 | Ionizable lipids and methods of manufacture and use thereof | NPC1L1, NSUN3, CETP | CASP3 2016/4885ALDH1A1 1813/4885MEN1 1850/4885 |
| US-20250352636-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | HNRNPH3, PARG, CPSF6 | CASP3 4027/4885ALDH1A1 4188/4885MEN1 1143/4885 |
| US-20250367131-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | NPC1L1, PLA2G4A, PLA2G2A | CASP3 3927/4885ALDH1A1 2988/4885MEN1 1295/4885 |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | CASP3 4716/4885ALDH1A1 4360/4885MEN1 3426/4885 |
| US-20060062822-A1 | Medical devices to treat or inhibit restenosis | ALDOA, AKR1B1, AKR1C2 | CASP3 3779/4885ALDH1A1 11/4885MEN1 2391/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | CASP3 3901/4885ALDH1A1 4064/4885MEN1 2224/4885 |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | RNMT, NSUN3, SARNP | CASP3 3627/4885ALDH1A1 2988/4885MEN1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.